Apogee Therapeutics (APGE) Common Equity (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $1.3 billion, up 86.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 86.5% YoY), and the FY2025 annual result was $903.9 million, up 26.1% from the prior year.
• Common Equity rose to $1.3 billion in Q1 2026 per APGE's latest filing, from $903.9 million in the prior quarter.
• Over five years, Common Equity peaked at $1.3 billion in Q1 2026 and troughed at -$64.4 million in Q2 2023.
• A 5-year average of $480.0 million and a median of $602.9 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 1353.08% in 2023, then soared 1818.32% in 2024.
• A 5-year view of Common Equity shows it stood at -$35.4 million in 2022, then soared by 1173.44% to $379.9 million in 2023, then surged by 88.67% to $716.8 million in 2024, then gained by 26.1% to $903.9 million in 2025, then surged by 38.93% to $1.3 billion in 2026.
• Business Quant data shows APGE's Common Equity at $1.3 billion in Q1 2026, $903.9 million in Q4 2025, and $586.3 million in Q3 2025.